Table 1 Baseline clinical characteristics
Total = 3817 | Low-intensity statin therapy (n = 931) | Moderate-intensity statin therapy group (n = 1602) | High-intensity statin therapy group (n = 1284) | p-value |
|---|---|---|---|---|
Age, year | 50 ± 12 | 53 ± 8 | 58 ± 8 | <0.001 |
Gender, male, n (%) | 466 (50.1) | 751 (46.9) | 761 (59.3) | <0.776 |
Hypertension, n (%) | 272 (29.2) | 488 (30.5) | 493 (38.4) | <0.001 |
Diabetes, n (%) | 21 (0.2) | 191 (11.9) | 211 (16.4) | <0.001 |
Dyslipidemia, n (%) | 136 (14.6) | 194 (12.1) | 242 (18.8) | <0.001 |
Familial history of CVA, n (%) | 121 (13.0) | 304 (19.0) | 500 (38.9) | 0.145 |
Body mass index, kg/m2 | 24.1 ± 3.8 | 24.6 ± 3.6 | 25.4 ± 3.0 | <0.001 |
Waist circumference, cm | 85 ± 9 | 87 ± 9 | 90 ± 9 | <0.001 |
Systolic BP, mm Hg | 120 ± 13 | 122 ± 13 | 128 ± 14 | <0.001 |
Diastolic BP, mm Hg | 120 ± 13 | 72 ± 9 | 77 ± 10 | <0.001 |
Heart rate, beats per minute | 62 ± 8 | 64 ± 9 | 64 ± 10 | 0.206 |
Smoking status, n (%) | 308 (33.1) | 144 (9.0) | 537 (41.8) | <0.001 |
Total cholesterol, mg/dL | 138 ± 19 | 201 ± 32 | 209 ± 39 | <0.001 |
Triglyceride, mg/dL | 148 ± 16 | 106 ± 75 | 141 ± 86 | <0.001 |
HDL-C, mg/dL | 50 ± 14 | 54 ± 13 | 47 ± 10 | <0.001 |
LDL-C, mg/dL | 59 ± 11 | 122 ± 28 | 130 ± 35 | <0.001 |
Fasting blood glucose, mg/dL | 91 ± 14 | 98 ± 24 | 105 ± 28 | <0.001 |
HbA1c, % | 5.5 ± 0.4 | 5.7 ± 0.8 | 5.9 ± 0.9 | <0.001 |
Fasting insulin, IU/L | 8.8 ± 7.0 | 8.0 ± 5.2 | 9.1 ± 6.5 | 0.246 |
HOMA-IR, | 1.9 ± 2.3 | 2.0 ± 1.6 | 2.4 ± 2.1 | 0.104 |
C reactive protein, mg/dL | 0.11 ± 0.37 | 0.17 ± 0.56 | 0.18 ± 0.44 | 0.099 |
Ten-year, ASCVDS, % | 2.1 ± 2.0 | 2.9 ± 1.9 | 12.6 ± 5.3 | <0.001 |
CACS | 2 ± 8 | 3 ± 2 | 98 ± 270 | <0.001 |